SAGA Diagnostics® Launches Ultrasensitive Pathlight™ MRD Test in Colorectal Cancer
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics® Presents Real-World Pathlight™ MRD Data at ASCO GI 2026
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics’ Pathlight™ MRD Further Demonstrates Clinical Validity In TNBC Trials Presented at SABCS
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics Showcases New Pathlight MRD Data at SABCS 2025
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
SAGA Diagnostics® to Present at the Jefferies Global Healthcare Conference in London 2025
We are pleased to announce that SAGA will be presenting at the Jefferies Global Healthcare Conference in London—celebrating the 16th anniversary of Europe’s largest healthcare-dedicated investor event.
SAGA Diagnostics® Announces Medicare Coverage for Pathlight™ MRD Test in Breast Cancer Across All Subtypes
Press Release Coverage marks a pivotal step in expanding access to ultra-sensitive MRD detection for breast cancer patients U.S. Medicare coverage decision reflects published, peer-reviewed clinical data demonstrating 100% sensitivity, 100% specificity, and a 13.7-month lead time versus standard-of-care clinical detection of recurrence across all subtypes and early stages of breast cancer MORRISVILLE, NC — […]
SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection
Press Release SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection Pathlight is a tumor-informed, multi-cancer MRD platform with its first indication in breast cancer Published, peer-reviewed clinical study demonstrates 100% sensitivity, 100% specificity, and a 13.7-month lead time to recurrence across all subtypes […]